Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
HEPARIN SODIUM 1,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Heparin binds to antithrombin III, inducing a conformational change that accelerates the inactivation of thrombin (factor IIa) and activated factor X (Xa), thereby preventing thrombus formation and extension.
Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.
Prophylaxis and treatment of venous thrombosis and pulmonary embolism,Atrial fibrillation with embolization,Treatment of acute coronary syndromes (e.g., unstable angina, non-ST-elevation myocardial infarction),Anticoagulation for extracorporeal circulation (e.g., hemodialysis, cardiopulmonary bypass),Off-label: Prevention of left ventricular thrombus after myocardial infarction
Treatment of herpes simplex virus (HSV) infections (genital herpes, herpes labialis, herpes simplex encephalitis),Treatment of varicella-zoster virus (VZV) infections (chickenpox, herpes zoster),Neonatal herpes simplex virus infection,Off-label: Prevention of HSV reactivation in immunocompromised patients, treatment of eczema herpeticum
IV infusion: Initial bolus 80 units/kg, then 18 units/kg/h continuous IV infusion; titrate to a PTT 1.5-2.5 times control. Subcutaneous: 5,000 units every 8-12 hours.
5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.
Terminal elimination half-life 1–2 hours (dose-dependent; increases with higher doses due to saturable clearance). Clinical context: shorter half-life after IV bolus, prolonged in hepatic/renal impairment.
Terminal elimination half-life in adults with normal renal function is 2.5-3.3 hours. In anuric patients, half-life extends to approximately 19.5 hours, necessitating dosage adjustment in renal impairment.
Heparin is partially metabolized by the liver (desulfation) and cleared by the reticuloendothelial system. At high doses, renal excretion of unchanged drug occurs. Heparin does not undergo significant cytochrome P450 metabolism.
Acyclovir is partially metabolized by aldehyde oxidase and alcohol dehydrogenase to 9-carboxymethoxymethylguanine and other minor metabolites. The majority (62-90%) is excreted unchanged in urine via glomerular filtration and tubular secretion.
Renal (primarily via reticuloendothelial system, desulfation, and degradation; small amount unchanged in urine <10%). Biliary/fecal excretion minor.
Primarily renal excretion via glomerular filtration and tubular secretion; approximately 62-91% of an administered dose is recovered unchanged in urine. Fecal excretion is minimal (<2%).
Extensive binding to antithrombin III (ATIII), heparin cofactor II, and other plasma proteins. Overall >90% bound; free fraction ~10%.
9-33% bound to plasma proteins; binding is concentration-independent and predominantly to albumin.
0.1–0.4 L/kg (small Vd, confined to plasma and extracellular fluid).
Approximately 0.7 L/kg, indicating distribution into total body water. Penetrates well into tissues, including cerebrospinal fluid (CSF concentrations ~50% of plasma).
SC: 20–30% (low and variable due to binding and degradation at injection site). IV: 100%.
Intravenous administration yields 100% bioavailability. Oral bioavailability is 15-30% (not applicable to IV formulation).
GFR 30-60 m L/min: reduce dose by 20-30%; GFR <30 m L/min: avoid or reduce dose by 50% and monitor a PTT closely.
Cr Cl >50 m L/min: no adjustment; Cr Cl 25-50 m L/min: 5-10 mg/kg every 12 hours; Cr Cl 10-25 m L/min: 5-10 mg/kg every 24 hours; Cr Cl <10 m L/min: 2.5-5 mg/kg every 24 hours; hemodialysis: give dose after dialysis.
Child-Pugh A: no adjustment; Child-Pugh B or C: consider dose reduction by 25-30% due to decreased antithrombin III levels.
No dose adjustment required for hepatic impairment; acyclovir is minimally metabolized by the liver.
IV infusion: 75 units/kg bolus, then 20-28 units/kg/h continuous infusion; titrate to a PTT 1.5-2.5 times control. Subcutaneous: 100-150 units/kg every 12 hours.
Neonates (0-3 months): 10 mg/kg IV every 8 hours for HSV; Infants and children (3 months-12 years): 10 mg/kg IV every 8 hours for HSV, 20 mg/kg IV every 8 hours for VZV; maximum dose 500 mg/m² per dose.
Elderly patients (≥70 years): lower initial bolus (50 units/kg) and infusion rate (15 units/kg/h); monitor a PTT closely due to increased bleeding risk.
Elderly patients may have reduced renal function; adjust dose based on Cr Cl and monitor for neurotoxicity (e.g., confusion, hallucinations).
Heparin is not intended for intramuscular use due to risk of hematoma. For full prescribing information, consult the manufacturer's labeling. Spinal/epidural hematomas have occurred in patients anticoagulated with heparin who receive neuraxial anesthesia or spinal puncture, leading to long-term or permanent paralysis. Risk is increased by indwelling epidural catheters, concomitant use of other anticoagulants, antiplatelet agents, or thrombolytics, and a history of traumatic or repeated epidural/spinal punctures. Monitor patients for signs and symptoms of neurological impairment.
None.
Risk of bleeding: Monitor activated partial thromboplastin time (a PTT) regularly; avoid in patients with active bleeding or bleeding disorders.,Heparin-induced thrombocytopenia (HIT): Monitor platelet counts; discontinue if HIT is suspected and consider alternative anticoagulation.,Hypersensitivity reactions: May cause urticaria, angioedema, anaphylaxis; use caution in patients with history of heparin allergy.,Heparin resistance: May occur in patients with antithrombin III deficiency or elevated factor VIII.,Use with caution in patients with renal impairment, liver disease, or recent surgery/trauma.
Renal impairment: Dose adjustment required; monitor renal function.,Neurotoxicity: May cause agitation, hallucinations, confusion, seizures (especially in elderly or renally impaired).,Crystalluria: Risk increased with rapid infusion or dehydration; ensure adequate hydration.,Hemolytic uremic syndrome/thrombotic thrombocytopenic purpura (HUS/TTP): Rare but serious, reported in immunocompromised patients.,Pregnancy: Use only if clearly needed (Category B).
Known hypersensitivity to heparin or pork products,Active major bleeding or conditions with high bleeding risk (e.g., hemophilia, thrombocytopenia),History of heparin-induced thrombocytopenia (HIT) or heparin-induced thrombocytopenia with thrombosis (HITT),Severe uncontrolled hypertension,Inability to perform regular coagulation monitoring,Suspected intracranial hemorrhage
Hypersensitivity to acyclovir, valacyclovir, or any component of the formulation.,Neonates: Use of bacteriostatic water-containing preparations (e.g., benzyl alcohol) is contraindicated.
No known food interactions. This is a low-concentration heparin flush solution for catheter maintenance and is not systemically absorbed in significant amounts.
No specific food interactions. Adequate fluid intake is recommended to prevent renal toxicity. Avoid concurrent use of nephrotoxic substances (e.g., certain NSAIDs, aminoglycosides) without medical supervision.
Heparin does not cross the placenta; no documented teratogenic risk. No increased risk of congenital anomalies reported. Pregnancy exposure is considered safe.
FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; use only if clearly needed.
Heparin is not excreted into breast milk due to high molecular weight and polarity. M/P ratio not determined. Considered compatible with breastfeeding.
Acyclovir excreted in breast milk at low levels; M/P ratio unknown. Typical infant dose ~0.6 mg/kg/day (2-3% of maternal IV dose). No adverse effects reported in breastfeeding infants. Compatible with breastfeeding; caution with high maternal doses.
Pregnancy may require increased doses due to expanded plasma volume and increased clearance; monitor a PTT and adjust dose accordingly. Initial doses generally unchanged, but higher cumulative doses may be needed to maintain therapeutic a PTT.
Increased renal clearance and volume of distribution in pregnancy may reduce acyclovir exposure. No dose adjustment routinely recommended; however, higher doses or more frequent dosing may be considered for severe infections. Monitor therapeutic response.
This is a heparinized saline solution (1 U/m L) primarily used for maintaining patency of indwelling catheters (e.g., peripheral IV, central lines, arterial lines). Do not use for systemic anticoagulation. Incompatible with many drugs; flush with plain saline before and after medication administration. Monitor for heparin-induced thrombocytopenia (HIT) with prolonged use. Use cautiously in patients with history of HIT or heparin allergy.
Acyclovir in sodium chloride 0.9% preservative-free is for IV administration only; do not administer IM or SC. Infuse over at least 1 hour to prevent renal tubular damage. Monitor renal function and adjust dose in renal impairment (Cr Cl <50 m L/min). Ensure adequate hydration (e.g., 500 m L IV fluids per gram acyclovir) to reduce risk of crystalluria. In obese patients, use ideal body weight for dosing. Phlebitis at infusion site is common; rotate sites.
This solution is used to keep your IV line open and prevent blood clots inside the catheter.,Tell your healthcare provider if you have any history of heparin allergy or a condition called heparin-induced thrombocytopenia (HIT).,Report any signs of bleeding, such as unusual bruising, blood in urine or stool, or bleeding from the catheter site.,Do not use this solution if it appears cloudy or contains particles.
This medication is given intravenously (into a vein) to treat viral infections.,Drink plenty of fluids before and during treatment to prevent kidney problems.,Report any pain, redness, or swelling at the injection site, or any lower back pain.,Tell your healthcare provider if you have kidney disease or are taking other medications that can affect the kidneys.,This drug does not cure herpes infections but helps reduce symptoms and recurrence.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Teriflunomide, the active metabolite of leflunomide, inhibits dihydroorotate dehydrogenase (DHODH), a key enzyme in de novo pyrimidine synthesis, exerting immunomodulatory effects. Acyclovir, an antiviral nucleoside analog, may inhibit organic anion transporter 3 (OAT3)-mediated renal tubular secretion of teriflunomide, leading to increased systemic exposure. Elevated teriflunomide concentrations can potentiate hepatotoxicity, myelosuppression, and immunosuppression, increasing the risk of infections and other adverse effects."
"The serum concentration of Acyclovir can be increased when it is combined with Tizanidine."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about HEPARIN SODIUM 1,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE, answered by our medical review team.
HEPARIN SODIUM 1,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Heparin binds to antithrombin III, inducing a conformational change that accelerates the inactivation of thrombin (factor IIa) and activated factor X (Xa), thereby preventing thrombus formation and extension.. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is a Electrolyte that works by Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between HEPARIN SODIUM 1,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of HEPARIN SODIUM 1,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: IV infusion: Initial bolus 80 units/kg, then 18 units/kg/h continuous IV infusion; titrate to a PTT 1.5-2.5 times control. Subcutaneous: 5,000 units every 8-12 hours.. The standard adult dose of ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is: 5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining HEPARIN SODIUM 1,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. HEPARIN SODIUM 1,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Heparin does not cross the placenta; no documented teratogenic risk. No increased risk of congenital anomalies reported. Pregnancy exposure is considered safe.. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is classified as Category A/B. FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; us. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.